BCRX - Biocryst Pharmaceuticals Inc.

BCRX Stock Chart

BCRX Profile

BioCryst Pharmaceuticals, Inc., a pioneering biotechnology firm, specializes in the discovery and development of novel, orally administered small-molecule medicines. Established in 1986 and headquartered in Durham, North Carolina, the company has made significant strides in advancing treatments for various diseases.

Currently, BioCryst Pharmaceuticals markets several key products, including peramivir injection, an intravenous neuraminidase inhibitor marketed under the RAPIVAB, RAPIACTA, and PERAMIFLU brands for treating acute uncomplicated influenza. Another prominent product is ORLADEYO, an oral serine protease inhibitor used to manage hereditary angioedema. Moreover, the company is actively advancing its pipeline with innovative candidates such as BCX9930, an oral factor D inhibitor undergoing Phase II clinical trials for complement-mediated diseases.

In addition to its proprietary pipeline, BioCryst collaborates extensively through partnerships and in-license agreements with leading entities in the pharmaceutical and research sectors. These collaborations include Torii Pharmaceutical Co., Ltd., Seqirus UK Limited, and Shionogi & Co., Ltd., among others. These partnerships enable BioCryst Pharmaceuticals to leverage complementary expertise and resources to accelerate the development and commercialization of cutting-edge therapies aimed at addressing unmet medical needs globally.

BCRX Revenue Chart

BCRX Earnings